Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New shockwave machine aims to blast kidney stones away

NCT ID NCT04771182

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new device called the Enhanced Lithotripsy System (ELS) that uses shockwaves from outside the body to break kidney stones into tiny pieces. The goal was to see if it could safely clear stones or leave only very small fragments (less than 3 mm) after up to two treatments. The study planned to include 25 adults with stones in the kidney or ureter, but it was stopped early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Feb 2019

Finished

Oct 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female aged ≥ 18 years 2. Provides written informed consent 3. Understands and accepts the study requirements 4. One urinary stone eligible for treatment (minimum) that is: 1. apparent on a computed tomography (CT) scan within 14 days prior to study enrollment 2. located within the renal pelvis or ureter 3. is ≥ 3 mm in at least one dimension and ≤ 10 mm in maximum 4. less than or equal to 10mm in maximum dimension and has an area less than 56mm2 as estimated by pre-procedure CT dimension as estimated by pre- procedure CT 5. Participants with two or more stones in one or both kidneys are admissible and must meet the following inclusion criteria: 1. Number of stones (≥ 3 mm) present on treated side is 2 or less 2. Untreated stones must not be anticipated to require treatment within 30 days of enrollment, as determined by the investigator Exclusion Criteria: 1. Age less than 18 years of age or over 75 years of age 2. Diagnosis of radiolucent stones 3. History of cystinuria 4. Urine pH below 5.5 5. Current untreated urinary tract infection 6. Pregnancy 7. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.) 8. Enrollment in another research study or previous participation within 30 days of enrollment. 9. Participant has planned general anesthesia during index procedure with American Society of Anesthesiologists (ASA) physical classification level of 3 or greater 10. Known sensitivity to possible medications used before, during, or after the ELS procedure, including but not limited to the following: sedative agents, general anaesthetics, topical anaesthetics, and opioid analgesics 11. Coagulation abnormality or taking prescription anticoagulants that cannot be stopped during treatment. Aspirin usage will be discontinued at least 7 days prior to enrollment at the discretion of the attending physician 12. Mobility issues - unable to comfortably lie still for up to 120 minutes or unable to roll from back to side 13. Known hypersensitivity to conductivity gel 14. Body mass index (BMI) ≥ 35 unless anticipated skin to stone distance (anticipated distance from site of ELS treatment head to stone per pre-operative CT) is \<135mm 15. Implanted spinal cord neurostimulator intrathecal pump or any device that may interfere with energy transmission 16. Participant has open wounds, lesions, dermatitis, or ischemic tissues in the treatment area 17. Participant has had a major surgery that removed tissue around the spinal cord (e.g. a laminectomy) within the treatment area 18. Participant will undergo treatment of a stone located in the distal ureter and has previous hernia repair or surgical mesh implanted in the inguinal/hypogastric regions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urinary stone are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Urinary Calculi urolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alpha West Mead Private Hospital PTY Limited

    Westmead, New Southwales, 2145, Australia

  • Austin Health

    Heidelberg, Victoria, 3084, Australia

  • Goldfields Urology

    Bendigo, Victoria, 3550, Australia

  • Macarthur Urology

    Campbelltown, New Southwales, 2560, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.